APA

Hájek R., Masszi T., Petrucci M. T., Palumbo A., Rosiñol L., Nagler A., Yong K. L., Oriol A., Minarik J., Pour L., Dimopoulos M. A., Maisnar V., Rossi D., Kasparu H., Van Droogenbroeck J., Yehuda D. B., Hardan I., Jenner M., Calbecka M., Dávid M., de la Rubia J., Drach J., Gasztonyi Z., Górnik S., Leleu X., Munder M., Offidani M., Zojer N., Rajangam K., Chang Y., San-Miguel J. F. & Ludwig H. (20170830). A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). : Leukemia.

Chicago

Hájek R, Masszi T, Petrucci M T, Palumbo A, Rosiñol L, Nagler A, Yong K L, Oriol A, Minarik J, Pour L, Dimopoulos M A, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda D B, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang Y-L, San-Miguel J F and Ludwig H. 20170830. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). : Leukemia.

Harvard

Hájek R., Masszi T., Petrucci M. T., Palumbo A., Rosiñol L., Nagler A., Yong K. L., Oriol A., Minarik J., Pour L., Dimopoulos M. A., Maisnar V., Rossi D., Kasparu H., Van Droogenbroeck J., Yehuda D. B., Hardan I., Jenner M., Calbecka M., Dávid M., de la Rubia J., Drach J., Gasztonyi Z., Górnik S., Leleu X., Munder M., Offidani M., Zojer N., Rajangam K., Chang Y., San-Miguel J. F. and Ludwig H. (20170830). A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). : Leukemia.

MLA

Hájek R, Masszi T, Petrucci M T, Palumbo A, Rosiñol L, Nagler A, Yong K L, Oriol A, Minarik J, Pour L, Dimopoulos M A, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda D B, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang Y-L, San-Miguel J F and Ludwig H. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). : Leukemia. 20170830.